Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.
Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.
复制标题
KRAS 和 NRAS 突变对接受西妥昔单抗加 FOLFOX4 一线治疗的转移性结直肠癌 (mCRC) 患者治疗结果的影响：OPUS 研究的新结果。
DOI：
10.1200/jco.2014.32.3_suppl.lba444
复制
发表时间：
2014
影响因子：
45.3
通讯作者：
C. Bokemeyer
中科院分区：
文献类型：
--
作者：
S. Tejpar;H. Lenz;C. Köhne;V. Heinemann;F. Ciardiello;R. Esser;F. Beier;C. Stroh;K. Duecker;C. Bokemeyer
LBA 444背景：KRAS外显子2密码子12/13野生型（wt）mCRC患者从一线FOLFOX 4加用西妥昔单抗中显著获益，与缓解和无进展生存期相关。KRAS外显子2密码子12/13突变患者未显示获益，临床结局有恶化趋势。研究方法：使用BEAMing技术对先前定义为KRAS密码子12/13 wt（n=179）的OPUS研究患者的肿瘤进行KRAS外显子3和4（8）以及NRAS外显子2、3和4（18）的特异性突变筛查。根据突变状态评估治疗结果。结果：118/179（66%）例患者的RAS肿瘤突变状态可评价。在36例（31%）患者中检测到筛选位点的突变。在RAS wt人群中，西妥昔单抗与FOLFOX 4联合治疗存在获益（表）。在总体RAS突变人群中，西妥昔单抗加用FOLFOX 4的临床结局不太有利，且无获益。结论：原发性结直肠癌患者应尽早诊断。
LBA444 Background: Patients with KRAS exon 2 codon 12/13 wild-type (wt) mCRC benefit significantly from the addition of cetuximab to first-line FOLFOX4 in relation to response and progression-free survival. Patients with KRAS exon 2 codon 12/13 mutations show no benefit with a trend to worse clinical outcomes. Methods: Tumors from OPUS study patients previously defined as KRAS codon 12/13 wt (n=179) were screened for specific mutations in KRAS exons 3 and 4 (8) and NRAS exons 2, 3, and 4 (18) using BEAMing technology. Treatment outcomes were assessed according to mutation status. Results: RAS tumor mutation status was evaluable for 118/179 (66%) patients. Mutations at the screened loci were detected in 36 (31%) patients. In the RAS wt population, there was benefit associated with the addition of cetuximab to FOLFOX4 (Table). In the overall RAS-mutant population, there was less favorable clinical outcome and no benefit from the addition of cetuximab to FOLFOX4. Conclusions: Patients with mCRC harboring any...